Becket Feierbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Becket Feierbach has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Abhishek Aggarwal
Gilead Sciences, Foster City, CA, USA
4 shared publicationsAnuj Gaggar
Gilead Sciences, Foster City, CA, USA
4 shared publicationsLi Li
Gilead Sciences, Foster City, CA, USA
4 shared publicationsPatrick Marcellin
Hôpital Beaujon, Clichy, France
4 shared publicationsVithika Suri
Gilead Sciences, Foster City, CA, USA
4 shared publicationsChristina Moon
Gilead Sciences, Foster City, CA, USA
3 shared publications
Latest Publications
- Open Access
- 26 December 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100664
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
- 26 December 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100664
Open AccessIntrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
- 14 August 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (5) , 1457-1451
Reply to: “Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection”
- 14 August 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (5) , 1457-1451
Reply to: “Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection”
- Open Access
- 1 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0262516
Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy
Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure. Nucleos(t)ide analogs do not directly eliminate the viral episome, therefore treatment cessation typically leads to rapid viral rebound. While treatment is effective, HBV DNA is still detectable (although not quantifiable) in the periphery of the majority of nucleos(t)ide analog treated HBV patients, even after prolonged treatment. Addressing whether the detectable HBV DNA represents infectious virus is a key unknown and has important implications for the development of a curative treatment for HBV. The minimum HBV genome equivalents required to establish infection in human liver chimeric mice was determined by titration of HBV patient sera and the infectivity in chimeric mice of serum from patients (n = 7) suppressed to the limit of detection on nucleos(t)ide analog therapy was evaluated. A minimum of 5 HBV genome equivalents were required to establish infection in the chimeric mice, confirming this model has sufficient sensitivity to determine whether serum from virally suppressed patients contains infectious virus. Strikingly, serum from 75% (n = 3 out of 4) of nucleos(t)ide-treated HBV patients with DNA that was detectable, but below the lower limit of quantitation, also established infection in the chimeric mice. These results demonstrate that infectious virus is still present in some HBV patients on suppressive nucleos(t)ide therapy. This residual virus may support viral persistence via continuous infection and explain the ongoing risk for HBV-related complications despite long-term suppression on therapy. Thus, additional treatment intensification may facilitate HBV cure.
- 1 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0262516
Open AccessOngoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy
Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure. Nucleos(t)ide analogs do not directly eliminate the viral episome, therefore treatment cessation typically leads to rapid viral rebound. While treatment is effective, HBV DNA is still detectable (although not quantifiable) in the periphery of the majority of nucleos(t)ide analog treated HBV patients, even after prolonged treatment. Addressing whether the detectable HBV DNA represents infectious virus is a key unknown and has important implications for the development of a curative treatment for HBV. The minimum HBV genome equivalents required to establish infection in human liver chimeric mice was determined by titration of HBV patient sera and the infectivity in chimeric mice of serum from patients (n = 7) suppressed to the limit of detection on nucleos(t)ide analog therapy was evaluated. A minimum of 5 HBV genome equivalents were required to establish infection in the chimeric mice, confirming this model has sufficient sensitivity to determine whether serum from virally suppressed patients contains infectious virus. Strikingly, serum from 75% (n = 3 out of 4) of nucleos(t)ide-treated HBV patients with DNA that was detectable, but below the lower limit of quantitation, also established infection in the chimeric mice. These results demonstrate that infectious virus is still present in some HBV patients on suppressive nucleos(t)ide therapy. This residual virus may support viral persistence via continuous infection and explain the ongoing risk for HBV-related complications despite long-term suppression on therapy. Thus, additional treatment intensification may facilitate HBV cure.
- Open Access
- 24 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 332-343
Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection
- 24 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 332-343
Open AccessMulti-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection
- Open Access
- 12 February 2022
- Published by Elsevier in JHEP Reports
- Vol. 4 (4) , 100449
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B
- 12 February 2022
- Published by Elsevier in JHEP Reports
- Vol. 4 (4) , 100449
Open AccessTargeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B
- Open Access
- 24 October 2021
- Published by Elsevier in JHEP Reports
- Vol. 4 (1) , 100388
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection
- 24 October 2021
- Published by Elsevier in JHEP Reports
- Vol. 4 (1) , 100388
Open AccessCharacterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection
- 1 June 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 292, 114117
Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds
- 1 June 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 292, 114117
Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e453-e454
FRI-149-Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e453-e454
FRI-149-Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients